阿巴拉契亚心理健康倡议(AMHI):一项在初级保健患者中治疗重性抑郁障碍的辅助性互联网认知行为疗法的实用性随机临床试验
该试验计划在美国家西弗吉尼亚州初级保健机构纳入3360例刚开始单用抗抑郁药治疗的重性抑郁障碍患者,随机分为单用药物、药物+自导互联网认知行为疗法、药物+指导互联网认知行为疗法三组,评估总体疗效及疗效异质性,主要结局为基于改良版以患者为中心的抑郁缓解问卷的发作缓解。
要点
- 研究纳入初级保健中刚开始单用抗抑郁药的重性抑郁障碍患者3360例。
- 患者随机等额分配至单用药物、药物+自导i-CBT、药物+指导i-CBT三组。
- 主要结局为基于改良版RDQ的发作缓解,将用机器学习估计疗效异质性。
核心结论
- 作者预期自导和指导i-CBT均比单用抗抑郁药改善结局,且不同患者附加i-CBT的比较优势会有显著差异。
- 作者希望建立稳定的个体化治疗规则,使患者和治疗提供者能协作决定何时应在抗抑郁药治疗中增加i-CBT。
研究设计与样本
- 实用性随机临床试验,计划纳入3360例在西弗吉尼亚州初级保健机构刚开始单用抗抑郁药治疗重性抑郁障碍的患者。
- 患者随机等额分配至单用抗抑郁药、抗抑郁药+自导i-CBT、抗抑郁药+指导i-CBT三组。
- 随机后第2、4、8、13、16、26、39和52周进行随访自报问卷。
- 主要目标为评估三组间总体比较治疗效果和估计疗效异质性。
- 主要结局为基于改良版以患者为中心的抑郁缓解问卷(RDQ)的发作缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder (MDD) is a leading cause of disease morbidity. Combined treatment with antidepressant medication (ADM) plus psychotherapy yields a much higher MDD remission rate than ADM only. But 77% of US MDD patients are nonetheless treated with ADM only despite strong patient preferences for psychotherapy. This mismatch is due at least in part to a combination of cost considerations and limited availability of psychotherapists, although stigma and reluctance of PCPs to refer patients for psychotherapy are also involved. Internet-based cognitive behaviorial therapy (i-CBT) addresses all of these problems. METHODS: Enrolled patients (n = 3360) will be those who are beginning ADM-only treatment of MDD in primary care facilities throughout West Virginia, one of the poorest and most rural states in the country. Participating treatment providers and study staff at West Virginia University School of Medicine (WVU) will recruit patients and, after obtaining informed consent, administer a baseline self-report questionnaire (SRQ) and then randomize patients to 1 of 3 treatment arms with equal allocation: ADM only, ADM + self-guided i-CBT, and ADM + guided i-CBT. Follow-up SRQs will be administered 2, 4, 8, 13, 16, 26, 39, and 52 weeks after randomization. The trial has two primary objectives: to evaluate aggregate comparative treatment effects across the 3 arms and to estimate heterogeneity of treatment effects (HTE). The primary outcome will be episode remission based on a modified version of the patient-centered Remission from Depression Questionnaire (RDQ). The sample was powered to detect predictors of HTE that would increase the proportional remission rate by 20% by optimally assigning individuals as opposed to randomly assigning them into three treatment groups of equal size. Aggregate comparative treatment effects will be estimated using intent-to-treat analysis methods. Cumulative inverse probability weights will be used to deal with loss to follow-up. A wide range of self-report predictors of MDD heterogeneity of treatment effects based on previous studies will be included in the baseline SRQ. A state-of-the-art ensemble machine learning method will be used to estimate HTE. DISCUSSION: The study is innovative in using a rich baseline assessment and in having a sample large enough to carry out a well-powered analysis of heterogeneity of treatment effects. We anticipate finding that self-guided and guided i-CBT will both improve outcomes compared to ADM only. We also anticipate finding that the comparative advantages of adding i-CBT to ADM will vary significantly across patients. We hope to develop a stable individualized treatment rule that will allow patients and treatment providers to improve aggregate treatment outcomes by deciding collaboratively when ADM treatment should be augmented with i-CBT. TRIAL REGISTRATION: ClinicalTrials.gov NCT04120285 . Registered on October 19, 2019.
引用
- Bossarte RM, Kessler RC, Nierenberg AA, et al. The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients. Trials. 2022. PMID: 35725644. doi:10.1186/s13063-022-06438-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。